Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, alleging that the company made false or misleading statements regarding its gene therapy product ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [3][4]. Group 1: Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for Duchenne muscular dystrophy, including the gene therapy product ELEVIDYS [3]. Group 2: Allegations and Impact - The lawsuit claims that during the class period, Sarepta failed to disclose significant safety risks associated with ELEVIDYS, inadequacies in clinical trial protocols, and the potential for adverse events that could jeopardize regulatory approvals [3]. - On March 18, 2025, Sarepta disclosed a patient death due to acute liver failure linked to ELEVIDYS, resulting in a stock price drop of over 27% [4]. - Following an April 4, 2025 announcement regarding a review by European regulatory authorities, Sarepta's stock fell an additional 7% after halting recruitment and dosing in certain clinical trials [5]. - A second patient death was reported on June 15, 2025, leading to a 42% decline in stock price as the company suspended shipments of ELEVIDYS for non-ambulatory patients [6]. - The FDA issued a Safety Communication on June 24, 2025, confirming investigations into the deaths, causing an additional 8% drop in Sarepta's stock [7].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Allegations and Claims - The lawsuit alleges that Sarepta misrepresented the safety profile of Elevidys, claiming that the benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance and Market Reaction - Following the announcement of a patient's death due to acute liver failure on March 18, 2025, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 to $73.54 per share [4]. - After a second patient death was reported on June 15, 2025, the stock fell by $15.24, or more than 42%, from $36.18 to $20.94 per share [4]. - A third patient death was disclosed on July 17, 2025, leading to another significant decline in stock price of over 40% on July 18, 2025 [5].

Core Viewpoint - Sarepta Therapeutics is expected to report second-quarter 2025 earnings on August 6, with significant increases in sales and earnings per share compared to the previous year, despite recent challenges related to safety issues with its gene therapy products [1][11]. Financial Performance - The Zacks Consensus Estimate for total sales is approximately $530 million and earnings per share (EPS) is $1.11, indicating a substantial increase from the prior year [1][11]. - Preliminary net product revenues for the second quarter are reported at $513 million, including $282 million from Elevidys sales [3][11]. - Adjusted R&D and SG&A expenses for the quarter are estimated to be around $294 million [3]. Product Portfolio and Market Challenges - Sarepta has four marketed products targeting Duchenne muscular dystrophy (DMD), including the gene therapy Elevidys and three PMO therapies [2]. - Recent safety concerns have arisen due to three patient deaths linked to its gene therapy treatments, leading to a temporary market withdrawal of Elevidys [4][5]. - The FDA has recently cleared Elevidys for use in ambulatory patients, allowing Sarepta to resume shipments [6]. Strategic Initiatives - To address safety issues, the company is developing a new protocol for Elevidys administration in non-ambulatory patients and plans to submit these findings to the FDA [7]. - A restructuring plan has been initiated to save nearly $400 million annually starting in 2026, which includes laying off 36% of its workforce, approximately 500 employees [8]. - Sarepta aims to generate around $300 million in annual savings by reprioritizing its pipeline, focusing on siRNA programs acquired from Arrowhead Pharmaceuticals [9]. Earnings Surprise History - The company's performance has been mixed, with earnings missing estimates in two of the last four quarters, resulting in a negative average surprise of 194.53% [12]. - The stock has underperformed the industry so far this year [12]. Earnings Prediction - Currently, Sarepta has an Earnings ESP of 0.00% and a Zacks Rank of 4 (Sell), indicating a low likelihood of an earnings beat [14].

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SRPT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 25, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the r ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sarepta Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their achievements in recovering hundreds of millions of dollars for investors [4]. - The firm has been recognized for its performance in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Sarepta made false and misleading statements regarding its gene therapy ELEVIDYS, which posed significant safety risks and failed to detect severe side effects during trials [5]. - It is claimed that the adverse events from ELEVIDYS treatment led to a halt in recruitment and dosing in trials, attracting regulatory scrutiny and increasing risks around the therapy's approvals [5].

Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly concerning the safety claims of their product Elevidys [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Allegations and Claims - The lawsuit alleges that Sarepta misrepresented the safety profile of Elevidys, claiming that the benefits outweighed the risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. Stock Performance and Market Reaction - Following the announcement of a patient's death due to acute liver failure after receiving Elevidys, Sarepta's stock price dropped by $27.81, or over 27%, from $101.35 on March 17, 2025, to $73.54 on March 18, 2025 [4]. - After a second patient death was reported on June 15, 2025, the stock fell by $15.24, or more than 42%, from $36.18 on June 13, 2025, to $20.94 on June 16, 2025 [4]. - A third patient death related to Elevidys was disclosed on July 17, 2025, leading to a further decline of over 40% in the stock price on July 18, 2025 [5]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with investors having until August 25, 2025, to seek lead plaintiff status [2].

Group 1: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - The class period for Sarepta is from June 22, 2023, to June 24, 2025, with a lead plaintiff deadline of August 25, 2025 [2] - The lawsuit alleges that Sarepta made materially false and misleading statements regarding its gene therapy ELEVIDYS, which was intended to treat Duchenne muscular dystrophy, leading investors to believe it was safe and had a positive revenue outlook [2] - Significant safety risks associated with ELEVIDYS were not disclosed, including severe side effects that led to the halting of trials and regulatory scrutiny [2][3] - Following the announcement of a patient death related to ELEVIDYS, Sarepta's stock price fell by $27.81 (27.44%) to close at $73.54 on March 18, 2025 [3] - Subsequent disclosures of additional patient deaths and regulatory investigations resulted in further stock price declines, with a notable drop of $15.24 (42.12%) to close at $20.91 on June 15, 2025 [3] Group 2: Petco Health and Wellness Company, Inc. (NASDAQ:WOOF) - The class period for Petco is from January 14, 2021, to June 5, 2025, with a lead plaintiff deadline of August 29, 2025 [4] - The lawsuit claims that Petco made materially false and misleading statements about its business operations, particularly regarding the sustainability of pandemic-related growth and the viability of its premium pet food business model [4][5] - Defendants allegedly overstated Petco's ability to achieve sustainable, profitable growth, with a specific reference to a share price of $95.85 on May 21, 2025 [5]

Core Insights - Sarepta Therapeutics announced a major restructuring involving a 36% workforce reduction, equating to 500 employees, aimed at saving approximately $400 million annually [1] - The FDA has mandated a black box warning for Sarepta's gene therapy drug, ELEVIDYS, due to risks of acute liver injury and acute liver failure [1] Legal Issues - A securities class action lawsuit has been filed against Sarepta, representing investors who acquired securities between June 22, 2023, and June 24, 2025 [2][4] - The lawsuit alleges that Sarepta misled investors regarding the safety and efficacy of ELEVIDYS, claiming the company portrayed the drug as safe while withholding critical risk information [4][5] Safety Concerns - The lawsuit highlights that Sarepta failed to disclose significant safety risks associated with ELEVIDYS and inadequacies in clinical trial protocols [5] - A timeline of events indicates that Sarepta reported a patient death during a trial on March 18, 2025, followed by further disclosures of deaths and regulatory scrutiny [6][7][8] Regulatory Scrutiny - On July 25, 2025, the European Medicines Agency rejected ELEVIDYS due to questions about its effectiveness, leading to a further decline in Sarepta's stock price [9]

NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/sarepta-lawsuit-submission-f ...

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...